These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 18173425)

  • 1. Dilated conjunctival vessels in a patient undergoing epoprostenol therapy.
    Foroozan R; Chan-Kai B; Marx DP
    Clin Exp Ophthalmol; 2007 Dec; 35(9):877-8. PubMed ID: 18173425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
    Matthes J; Mathen F; Herzig S; Wassermann K
    Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
    [No Abstract]   [Full Text] [Related]  

  • 3. Epoprostenol for primary pulmonary hypertension.
    Med Lett Drugs Ther; 1996 Feb; 38(968):14-5. PubMed ID: 8592477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treprostinil (Remodulin) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):80-2. PubMed ID: 12237619
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging therapies for pulmonary hypertension: striving for efficacy and safety.
    Kao PN; Faul JL
    J Am Coll Cardiol; 2003 Jun; 41(12):2126-9. PubMed ID: 12821235
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of acute vasoresponsiveness in patients with pulmonary hypertension: treatment implications.
    Arunthari V; Heckman MG; Burger CD
    South Med J; 2010 Jul; 103(7):630-4. PubMed ID: 20531064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable outcome of pregnancy with an elective use of epoprostenol and sildenafil in women with severe pulmonary hypertension.
    Goland S; Tsai F; Habib M; Janmohamed M; Goodwin TM; Elkayam U
    Cardiology; 2010; 115(3):205-8. PubMed ID: 20173324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension.
    Greig SL; Scott LJ; Plosker GL
    Am J Cardiovasc Drugs; 2014 Dec; 14(6):463-70. PubMed ID: 25312243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary pulmonary hypertension. Treatment with prostacyclin I2 (epoprostenol)].
    Vicente R; Ramos F; Morales P
    Rev Esp Anestesiol Reanim; 1999; 46(6):274. PubMed ID: 10439652
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
    Myers SA; Ahearn GS; Angelica Selim M; Tapson VF
    J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults.
    Buckley MS; Feldman JP
    Pharmacotherapy; 2010 Jul; 30(7):728-40. PubMed ID: 20575636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sudden death during a change in treatment for pulmonary hypertension.
    Brun H; Holmström H; Thaulow E
    Cardiol Young; 2005 Apr; 15(2):223-5. PubMed ID: 15845169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy.
    Ozkan M; Dweik RA; Laskowski D; Arroliga AC; Erzurum SC
    Lung; 2001; 179(4):233-43. PubMed ID: 11891614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scheduled perioperative switch from oral sildenafil to intravenous epoprostenol in a patient with Eisenmenger syndrome undergoing a sigmoidectomy.
    Moriyama K; Uzawa K; Iijima T; Kotani M; Moriyama K; Ohashi Y; Satoh T; Yorozu T
    J Clin Anesth; 2012 Sep; 24(6):487-9. PubMed ID: 22762976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous epoprostenol for primary pulmonary hypertension.
    Schulze-Neick I; Lange PE; Haas NA
    N Engl J Med; 1996 May; 334(22):1477; author reply 1477-8. PubMed ID: 8618596
    [No Abstract]   [Full Text] [Related]  

  • 17. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
    Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.